Use of cefuroxime for women with community- onset acute pyelonephritis caused by cefuroxime- susceptible or -resistant Escherichia coli
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Efforts to decrease the use of extended-spectrum cephalosporins are required to prevent the selection and transmission of multi-drug resistant pathogens, such as extended-spectrum b-lactamase (ESBL)-producing Enterobacteriaceae. The objectives of this study were to assess the clinical efficacy of intravenous cefuroxime as an empirical antibiotic for the treatment of hospitalized women with acute pyelonephritis (APN) caused by Escherichia coli. Methods: We analyzed the clinical and microbiologic database of 328 hospitalized women with community-onset APN. Results: Of 328 women with APN, 22 patients had cefuroxime-resistant E. coli APN, and 306 patients had cefuroxime-susceptible E. coli APN. The early clinical success rates were significantly higher (p = 0.001) in the cefuroxime-susceptible group (90.8%, 278/306) than in the cefuroxime-resistant group (68.2%, 15/22) at 72 hours. The clinical cure rates at 4 to 14 days after completing antimicrobial therapy were not significantly different in the cefuroxime-resistant or -susceptible groups, with 88.2% (15/17) and 97.8% (223/228; p = 0.078), respectively. The microbiological cure rates were not significantly different and were 90.9% (10/11) and 93.4% (128/137), respectively (p =0.550). The median duration of hospitalization in the cefuroxime-resistant and -susceptible groups was 10 days (interquartile range [IQR], 8 to 13) and 10 days (IQR, 8 to 14), respectively (p=0.319). Conclusions: Cefuroxime, a second-generation cephalosporin, can be used for the initial empirical therapy of community-onset APN if tailored according to uropathogen identification and susceptibility results, especially in areas where the prevalence rate of ESBL-producing uropathogens is low.
Abstract
Background/Aims: Efforts to decrease the use of extended-spectrum cephalosporins are required to prevent the selection and transmission of multi-drug resistant pathogens, such as extended-spectrum b-lactamase (ESBL)-producing Enterobacteriaceae. The objectives of this study were to assess the clinical efficacy of intravenous cefuroxime as an empirical antibiotic for the treatment of hospitalized women with acute pyelonephritis (APN) caused by Escherichia coli. Methods: We analyzed the clinical and microbiologic database of 328 hospitalized women with community-onset APN. Results: Of 328 women with APN, 22 patients had cefuroxime-resistant E. coli APN, and 306 patients had cefuroxime-susceptible E. coli APN. The early clinical success rates were significantly higher (p = 0.001) in the cefuroxime-susceptible group (90.8%, 278/306) than in the cefuroxime-resistant group (68.2%, 15/22) at 72 hours. The clinical cure rates at 4 to 14 days after completing antimicrobial therapy were not significantly different in the cefuroxime-resistant or -susceptible groups, with 88.2% (15/17) and 97.8% (223/228; p = 0.078), respectively. The microbiological cure rates were not significantly different and were 90.9% (10/11) and 93.4% (128/137), respectively (p =0.550). The median duration of hospitalization in the cefuroxime-resistant and -susceptible groups was 10 days (interquartile range [IQR], 8 to 13) and 10 days (IQR, 8 to 14), respectively (p=0.319). Conclusions: Cefuroxime, a second-generation cephalosporin, can be used for the initial empirical therapy of community-onset APN if tailored according to uropathogen identification and susceptibility results, especially in areas where the prevalence rate of ESBL-producing uropathogens is low.
참고문헌 (19)
- O’Callaghan CH, "Cefuroxime, a new cephalosporin antibiotic: activity in vitro", Antimicrob Agents Chemother, 9, pp.511~519 (1976)
- Jones RN, "Cefuroxime, a new parenteral cephalosporin:collaborative in vitro susceptibility comparison with cephalothin against 5,887 clinical bacterial isolates", Antimicrob Agents Chemother, 12, pp.47~50 (1977)
- Roberts AP, "The sensitivity of urinary isolates to cefuroxime, a new beta-lactamase stable cephalosporin", Curr Med Res Opin, 7, pp.5~13 (1980)
- Gupta K, "International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases", Clin Infect Dis, 52, pp.e103~e120 (2011)
- Ramakrishnan K, "Diagnosis and management of acute pyelonephritis in adults", Am Fam Physician, 71, pp.933~942 (2005)
- 임승관, "Change of Antimicrobial Susceptibility among Escherichia coli Strains Isolated from Female Patients with Community-Onset Acute Pyelonephritis", Yonsei Medical Journal, 53(1), pp.164~171 (2012), 연세대학교의과대학
- Wie SH, "Use of gentamicin for women with community-acquired uncomplicated acute pyelonephritis caused by gentamicin-susceptible or -resistant Escherichia coli: 10-year experience", Microb Drug Resist, 19, pp.316~322 (2013)
- Naber KG, "Piperacillin 2 g", tazobactam 0.5 g is as effective as imipenem 0.5 g, Int J Antimicrob Agents, pp.2002, 19[DOI]
- Paterson DL, "Extended-spectrum beta-lactamases:a clinical update", Clin Microbiol Rev, 18, pp.657~686 (2005)
- Jeon JH, "Empirical use of ciprofloxacin for acute uncomplicated pyelonephritis caused by Escherichia coli in communities where the prevalence of fluoroquinolone resistance is high", Antimicrob Agents Chemother, 56, pp.3043~3046 (2012)
- Shin J, "Fluoroquinolone resistance in uncomplicated acute pyelonephritis: epidemiology and clinical impact", Microb Drug Resist, 18, pp.169~175 (2012)
- Ronald AR, "Complicated urinary tract infections", Infect Dis Clin North Am, 11, pp.583~592 (1997)
- Safrin S, "Pyelonephritis in adult women: inpatient versus outpatient therapy", Am J Med, 85, pp.793~798 (1988)
- Clinical and Laboratory Standard Institute, "Performance Standards for Antimicrobial Susceptibility Testing: 15th Informational Supplement CLSI Document M100-S15", CLSI, ~ (2005)
- Yu VL, "An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome", Clin Infect Dis, 37, pp.230~237 (2003)
- Pitout JD, "Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community", J Antimicrob Chemother, 56, pp.52~59 (2005)
- Kang CI, "Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta-lactamase-producing Escherichia coli", Int J Antimicrob Agents, 36, pp.284~287 (2010)
- Rodriguez-Bano J, "Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: risk factors and prognosis", Clin Infect Dis, 50, pp.40~48 (2010)
- Calbo E, "Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases", J Antimicrob Chemother, 57, pp.780~783 (2006)